小分子化合物抗病毒治疗丙型肝炎肝硬化

doi:10.3969/j.issn.1672-5069.2016.04.004

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (4): 398-400.doi: 10.3969/j.issn.1672-5069.2016.04.004

小分子化合物抗病毒治疗丙型肝炎肝硬化

张霞霞, 徐小元

100034 北京市北京大学第一医院感染疾病科

收稿日期:2016-05-05 出版日期:2016-07-30 发布日期:2016-08-31
通讯作者: 徐小元,E-mail: xiaoyuanxu6@163.com
作者简介:张霞霞,女,28岁,博士研究生,主要从事病毒性肝炎的研究。E-mail: bdzxx1988@163.com

Renewed regimen of direct-acting antiviral agents in treatment of patients with hepatitis C-induced liver cirrhosis

Zhang Xiaxia, Xu Xiaoyuan

Department of Infectious Diseases,First Hospital,Peking University,Beijing 100034,China

Received:2016-05-05 Online:2016-07-30 Published:2016-08-31
Contact: Xu Xiaoyuan, E-mail: xiaoyuanxu6@163.com

摘要/Abstract

关键词: 肝硬化, 丙型肝炎, 直接抗病毒药物, 临床方案

Key words: Liver cirrhosis, Hepatitis C, Direct-acting antiviral agents, Regimen

张霞霞, 徐小元. 小分子化合物抗病毒治疗丙型肝炎肝硬化[J]. 实用肝脏病杂志, 2016, 19(4): 398-400.

Zhang Xiaxia, Xu Xiaoyuan. Renewed regimen of direct-acting antiviral agents in treatment of patients with hepatitis C-induced liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 398-400.

参考文献

[1] Coppola N,Minichini C,Starace M,et al:Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. J Med Virol,2,16.doi:10.1002/jmv.24527[ahead of print].
[2] Tamori A,Enomoto M,Kawada N. Recent advances in antiviral therapy for chronic hepatitis C. Mediators Inflamm,2016,2016:6841628.doi:10.1155/2016/6841628.
[3] Panel AIHG. Hepatitis C guidance:AASLD-IDSA recommendations for testing,managing,and treating adults infected with hepatitis C virus. Hepatology,2015,62:932-954.doi:10.1002/hep.27950.
[4] Morgan RL,Baack B,Smith BD,et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med,2013,158:329-337.doi:10.7326/0003-4819-158-5-201303050-00005.
[5] Sulkowski MS,Vargas HE,Di Bisceglie AM,et al. Effectiveness of simeprevir plus sofosbuvir,with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology,2016,150:419-429.doi:10.1053/j.gastro.2015.10.013.
[6] Mangia A,Arleo A,Copetti M,et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int,2016.doi:10.1111/liv.13069[ahead of print].
[7] Leroy V,Angus P,Bronowicki JP,et al. Daclatasvir,sofosbuvir,and ribavirin for hepatitis C virus genotype 3 and advanced liver disease:A randomized phase III study（ALLY-3+）. Hepatology,2016.doi:10.1002/hep.28473[ahead of print].
[8] Keating GM:Ledipasvir/sofosbuvir:a review of its use in chronic hepatitis C. Drugs,2015,75:675-685.
[9] Manns M,Samuel D,Gane EJ,et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease:a multicentre, open-label,randomised,phase 2 trial. Lancet Infect Dis,2016.doi:10.1016/S1473-3099（16）00052-9[ahead of print].
[10] Poordad F,Schiff ER,Vierling JM,et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology,2016.doi:10.1002/hep.28446[ahead of print].
[11] Foster GR,Irving WL,Cheung MC,et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol,2016.doi:10.1016/j.jhep.2016.01.029[ahead of print].
[12] Wyles D,Pockros P,Morelli G,et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology,2015,61:1793-1797.
[13] Modi AA,Nazario H,Trotter JF,et al. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transplant,2016,22:281-286.
[14] Papadopoulos N,Deutsch M,Georgalas A,et al. Simeprevir and sofosbuvir combination treatment in a patient with HCV cirrhosis and HbS Beta 0-thalassemia:Efficacy and safety despite baseline hyperbilirubinemia:Case reports. Hematology,2016, 2016:7635128.doi:10.1155/2016/7635128[ahead of print].
[15] Curry MP,Forns X,Chung RT,et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology,2015,148:100-107 e101.
[16] Afdhal N,Reddy KR,Nelson DR,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med,2014,370:1483-1493.
[17] Andreone P,Colombo MG,Enejosa JV,et al. ABT-450,ritonavir,ombitasvir,and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology,2014,147:359-365-e351.
[18] Lawitz E,Sulkowski MS,Ghalib R,et al. Simeprevir plus sofosbuvir,with or without ribavirin,to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet,2014,384:1756-1765.
[19] Kahveci AS,Tahan V. Sofosbuvir and Velpatasvir:A complete pan-genotypic treatment for HCV patients. Turkish J Gastroenterol,2016,27:205-206.
[20] Feld JJ,Jacobson IM,Hezode C,et al. Sofosbuvir and Velpatasvir for HCV Genotype 1,2,4,5,and 6 Infection. New Engl J Med,2015,373:2599-2607.
[21] Foster GR,Afdhal N,Roberts SK,et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New Engl J Med,2015,373:2608-2617.
[22] Curry MP,O'Leary JG,Bzowej N,et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. New Engl J Med,2015,373:2618-2628.
[23] Alric L,Bonnet D. Grazoprevir+elbasvir for the treatment of hepatitis C virus infection:Expert opinion. Pharmacotherapy,2016,17:735-742.
[24] Roth D,Nelson DR,Bruchfeld A,et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease（the C-SURFER study）:a combination phase 3 study. Lancet,2015,386:1537-1545.
[25] Chen T,Terrault N. Treatment of chronic hepatitis C in patients with cirrhosis:Current opinion. Gastroenterology,2016,32:143-151.
[26] Hsu CS,Kao JH. Management of hepatitis C patients with decompensated liver disease. Gastroenterol Hepatol,2016:1-10.doi:10.1586/17474124.2016.1143775[ahead of print].

小分子化合物抗病毒治疗丙型肝炎肝硬化

Renewed regimen of direct-acting antiviral agents in treatment of patients with hepatitis C-induced liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[3]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[4]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[5]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[6]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[7]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[8]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[9]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[10]	王月圆, 王燕, 张丹丹. 奥曲肽辅助特利加压素治疗失代偿期肝硬化并发肝肾综合征患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(5): 684-687.
[11]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[12]	丹珠永吉, 刘芝兰, 禄艳艳, 蒋汉梅. 内镜下序贯套扎和硬化剂治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效及对血流动力学的影响对比研究*[J]. 实用肝脏病杂志, 2019, 22(5): 692-695.
[13]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[14]	赵芳芳, 翟永贞, 冯国和. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(5): 700-703.
[15]	陈山, 庄华帅, 邢诒喜, 吴直佳. 美罗培南治疗肝硬化并发上消化道出血患者对感染预防和再出血的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 704-707.